New Drug Shows Promise in Treating Core Autism Symptoms, Heralded as Potential 'Ozempic of Autism'
An experimental oral medication, L1-79, has demonstrated significant results in early trials for autism spectrum disorder, sparking hope and comparison to the diabetes drug Ozempic.
An experimental oral drug, currently designated L1-79, is showing significant promise in treating the core symptoms of autism spectrum disorder (ASD), leading some to dub it the "Ozempic of autism." Early clinical trial results suggest the medication can lead to rapid improvements in individuals with ASD.
Joshua Turteltaub, 27, who was diagnosed with autism at two and a half years old, experienced dramatic changes shortly after beginning L1-79. A week after his first dose, he uttered the word "movie" while watching a film. His ability to remain at ease for extended periods also improved; he was able to sit through his grandfather's funeral, an event that would typically have been overwhelming.
The drug's clinical trial leader expressed astonishment at the results. "We've had over 100 participants in the FDA studies, and there have been no serious side effects to date," stated Joshua's doctor, who led the trials. The doctor added that he "almost fainted" upon seeing the efficacy of the treatment.
L1-79 is an oral medication designed to target the fundamental symptoms associated with autism spectrum disorder. The development and potential widespread adoption of this drug are being closely watched, with comparisons to the significant impact of drugs like Ozempic on other medical fields.
Further clinical studies and regulatory approvals will be necessary before L1-79 can become widely available. However, the early findings present a significant potential breakthrough for individuals and families affected by autism spectrum disorder.